Toward user-friendly and evidence-based practice guidelines for hepatocellular carcinoma

키워드

참고문헌 (18)

1. Korean Liver Cancer Association (KLCA), "2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma", Clinical and Molecular Hepatology, 28(4), pp.583~705 (2022), 대한간학회
2. Park JW, "Practice guideline for diagnosis and treatment of hepatocellular carcinoma", Korean J Hepatol, 10, pp.88~98 (2004)
3. Myung Ji Goh, "Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspective", Clinical and Molecular Hepatology, 29(2), pp.197~205 (2023), 대한간학회
4. Gavriilidis P, "Evaluation of the current guidelines for resection of hepatocellular carcinoma using the Appraisal of Guidelines for Research and Evaluation II instrument", J Hepatol, 67, pp.991~998 (2017)
5. Yoon JH, "A comparison of biannual two-phase low-dose liver CT and US for HCC surveillance in a group at high risk of HCC development", Liver Cancer, 9, pp.503~517 (2020)
6. Kim SY, "MRI with liverspecific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma", JAMA Oncol, 3, pp.456~463 (2017)
7. Chan MV, "Noncontrast MRI for hepatocellular carcinoma detection : a systematic review and meta-analysis-A potential surveillance tool?", Clin Gastroenterol Hepatol, 20, pp.44~56 (2022)
8. An C, "Noncontrast magnetic resonance imaging versus ultrasonography for hepatocellular carcinoma surveillance(MIRACLE-HCC) : study protocol for a prospective randomized trial", BMC Cancer, 18, pp.915~ (2018)
9. 한국 간 암 스터디그룹, "2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma", Gut and Liver, 9(3), pp.267~317 (2015), 거트앤리버 소화기연관학회협의회
10. 김남중, "Noninvasive Diagnostic Criteria of the Revised 2014 the Korean Liver Cancer Study Group and the National Cancer Center Guideline for Subcentimetersized Hepatocellular Carcinoma: Is It Too Strict?", Journal of Liver Cancer, 18(1), pp.44~50 (2018), 대한간암학회[DOI]
11. Fukami Y, "Liver resection for multiple hepatocellular carcinomas: A Japanese nationwide survey", Ann Surg, 272, pp.145~154 (2020)
12. Kokudo T, "Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion", J Hepatol, 65, pp.938~943 (2016)
13. "A study of atezolizumab plus bevacizumab versus active surveillance as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after surgical resection or ablation (IMbrave050)"[URL]
14. Vilgrain V, "Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial", Lancet Oncol, 18, pp.1624~1636 (2017)
15. Chow PKH, "SIRveNIB: Selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma", J Clin Oncol, 36, pp.1913~1921 (2018)
16. Finn RS, "Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma", N Engl J Med, 382, pp.1894~1905 (2020)
17. Abou-Alfa GK, "Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma", NEJM Evid (2022)[DOI]
18. Yoo C, "Clinical outcomes with multikinase inhibitors after progression on firstline atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma : A multinational multicenter retrospective study", Liver Cancer, 10, pp.107~114 (2021)

관련 논문AI추천